ReviewOncotarget2018
Natural killer cells as a therapeutic tool for infectious diseases - current status and future perspectives.
Review in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 41 citations in OpenAlex.
- Peptidoglycan-loaded PLGA-PVA nanoparticles sustain NOD2 and IFN-γ transcription in NK-92 cells beyond nanoparticle withdrawal.Archives of microbiology · 2026Article
- Autophagy-driven MHC-I downregulation enables NK cell-mediated clearance of intracellular uropathogenicAnimal cells and systems · 2026Article
- CD8α marks a Mycobacterium tuberculosis-reactive human NK cell population with high activation potential.Scientific reports · 2025Article
- Between good and evil: Complexation of the human cathelicidin LL-37 with nucleic acids.Biophysical journal · 2024Review
- Loss of circulating CD8αbioRxiv : the preprint server for biology · 2024Article
- Review
- Natural Killer Cells and Cytotoxic T Cells: Complementary Partners against Microorganisms and Cancer.Microorganisms · 2024Review
- Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS.Pathogens (Basel, Switzerland) · 2023Review
- Cytometric analysis reveals an association between allergen-responsive natural killer cells and human peanut allergy.The Journal of clinical investigation · 2022Article
- Natural killer cells kill extracellular Pseudomonas aeruginosa using contact-dependent release of granzymes B and H.PLoS pathogens · 2022Article
- In quest of a new therapeutic approach in COVID-19: the endocannabinoid system.Drug metabolism reviews · 2021Article
- Cell therapy strategies for COVID-19: Current approaches and potential applications.Science advances · 2021Review
- Article
- Fatty acids promote the expansion of NK-92 cells in vitro by improving energy metabolism.Applied microbiology and biotechnology · 2021Article
- Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future.Stem cell research & therapy · 2021Review
- Natural Killer Cell Line NK-92-Mediated Damage of Medically Important Fungi.Journal of fungi (Basel, Switzerland) · 2021Article
- The Interactions BetweenFrontiers in microbiology · 2021Review
- Polytherapeutic strategies with oncolytic virus-bortezomib and adjuvant NK cells in cancer treatment.Journal of the Royal Society, Interface · 2021Article
- Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation.Clinical microbiology reviews · 2020Review
- Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.Planta medica · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural Killer (NK) cells are involved in the host immune response against infections due to viral, bacterial and fungal pathogens, all of which are a significant cause of morbidity and mortality in immunocompromised patients. Since the recovery of the immune system has a major impact on the outcome of an infectious complication, there is major interest in strengthening the host response in immunocompromised patients, either by using cytokines or growth factors or by adoptive cellular therapies transfusing immune cells such as granulocytes or pathogen-specific T-cells. To date, relatively little is known about the potential of adoptively transferring NK cells in immunocompromised patients with infectious complications, although the anti-cancer property of NK cells is already being investigated in the clinical setting. This review will focus on the antimicrobial properties of NK cells and the current standing and future perspectives of generating and using NK cells as immunotherapy in patients with infectious complications, an approach which is promising and might have an important clinical impact in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.